Abemaciclib - Eli Lilly and Company
Alternative Names: Abemaciclib mesylate; Bemaciclib; Bemaciclib mesylate; LY 2835219; Verzenio; VerzeniosLatest Information Update: 01 Jul 2024
At a glance
- Originator Eli Lilly and Company
- Developer Boehringer Ingelheim; Dana-Farber Cancer Institute; Eli Lilly; Eli Lilly and Company; Jules Bordet Institute; M. D. Anderson Cancer Center; Memorial Sloan-Kettering Cancer Center; Merck Sharp & Dohme; UCLAs Jonsson Comprehensive Cancer Center; Washington University School of Medicine
- Class Aminopyridines; Antineoplastics; Benzimidazoles; Fluorinated hydrocarbons; Piperazines; Pyrimidines; Small molecules
- Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Breast cancer
- Phase III HER2 negative breast cancer; Liposarcoma; Prostate cancer
- Phase II Adenocarcinoma; Brain cancer; Cholangiocarcinoma; Endometrial cancer; Ewing's sarcoma; Fallopian tube cancer; Glioblastoma; Mantle-cell lymphoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Solid tumours; Urogenital cancer
- Phase I/II Head and neck cancer
- Phase I Myelofibrosis
- No development reported Cancer; Renal cell carcinoma
Most Recent Events
- 27 Jun 2024 phase-I development in Breast-cancer(Combination therapy, Late-stage disease, Metastatic disease) is ongoing in Finland, Denmark (PO, Tablet) (NCT03099174)
- 27 Jun 2024 Phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease) is ongoing in Spain, Japan, France, Finland, Denmark, USA, (PO) (NCT03099174)
- 26 Jun 2024 Eli Lilly and Company terminates a phase-III clinical trials in Breast cancer (Combination therapy, Early-stage disease, Second-line therapy or greater) in Mexico, Israel, Hungary, Greece, France, China, Brazil, Austria, Argentina, USA, Australia, Japan, South Korea, Taiwan, USA, Austria, Japan, Germany, Italy, Spain, Switzerland and United Kingdom (PO) due to inability to enroll study participants (NCT04752332)